Rivaroxaban
| Autor: | Singh R; Nepalese Army Institute of Health Sciences- College of Medicine, Tribhuvan University, Emmady PD; UNC school of Medicine, Atrium Health |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | 2022 Jan. |
| Abstrakt: | Rivaroxaban is used to treat and manage venous thromboembolism as a postoperative thromboprophylaxis for patients undergoing orthopedic surgery to prevent stroke in patients with non-valvular atrial fibrillation and recently has received approval as an add-on drug for secondary prevention of acute coronary syndrome and peripheral arterial disease. It is a novel oral anticoagulant (NOAC) and is commonly referred to as a blood thinner agent. This activity reviews the indications, contraindications, activity, adverse events, and other key elements of rivaroxaban therapy in the clinical setting as relates to the essential points needed by members of an interprofessional team managing the care of patients with venous and arterial thromboembolism (VTE) and its related conditions and sequelae. (Copyright © 2022, StatPearls Publishing LLC.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|